In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013

Diagn Microbiol Infect Dis. 2014 Dec;80(4):311-5. doi: 10.1016/j.diagmicrobio.2014.09.003. Epub 2014 Sep 16.

Abstract

Gram-positive pathogens isolated in 15 Canadian hospital laboratories between 2011 and 2013 were tested for susceptibility to oritavancin and comparative antimicrobial agents using the Clinical and Laboratory Standards Institute broth microdilution method. Oritavancin demonstrated in vitro activity equivalent to, or more potent than, vancomycin, daptomycin, linezolid, and tigecycline against the isolates of methicillin-susceptible Staphylococcus aureus (n=1460; oritavancin MIC90, 0.06 μg/mL; 99.7% oritavancin-susceptible), methicillin-resistant S. aureus (n=427; oritavancin MIC90, 0.06 μg/mL; 99.5% oritavancin-susceptible), Streptococcus pyogenes (n=132; oritavancin MIC90, 0.25 μg/mL; 99.2% oritavancin-susceptible), Streptococcus agalactiae (n=156; oritavancin MIC90, 0.12 μg/mL; 100% oritavancin-susceptible), and Enterococcus faecalis (n=304; oritavancin MIC90, 0.06 μg/mL; 98.7% oritavancin-susceptible) tested.

Keywords: MRSA; Oritavancin; Skin and soft tissue infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Canada
  • Drug Resistance, Bacterial / drug effects
  • Enterococcus faecalis / drug effects
  • Glycopeptides / administration & dosage
  • Glycopeptides / pharmacology*
  • Gram-Positive Bacteria / drug effects*
  • Gram-Positive Bacteria / isolation & purification
  • Gram-Positive Bacterial Infections / microbiology*
  • Humans
  • Laboratories, Hospital
  • Lipoglycopeptides
  • Methicillin-Resistant Staphylococcus aureus / drug effects
  • Microbial Sensitivity Tests
  • Vancomycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Glycopeptides
  • Lipoglycopeptides
  • Vancomycin
  • oritavancin